Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (13954)	7/4/2000 10:36:32 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

""if you think about it it will not be approved for an indication that can be cured better by something already the standard of care." >wrong george. I can be approved, but may not be well used. Robert, how does one convince the FDA taht there is a statistical significant benefit to ones new drug when the standard of care works better? My point was not to argue this point with Cacaito. To insist that Neuprex will be approved even if thae standard of care IS BETTER, gets a bit silly. My belief is that in many indications it will work better. The trauma trail failed because if the subject group did not get the indication or illness one expected the loss of blood to produce there was nothing to cure. How does one prove the drug effective when not enough subjects were even ill? Robert I agreee you taught me a tremendous amount. I will never be able to best you. Nor do I think about trying to best any poster. The well intentioned posters, Cacaito is certainly one, are involved in a process of sharing. Sometimes though, it seems that in your desire to prove that you know more, as indeed you do, you step on my arguments, which are if you think about them more alligned with your line of thought than you first might think. Perhaps this is because of the tone of my post. Can't tell. Anyway, thanks for the kind words.